Loading chat...
OK HB1416
Bill
Status
3/4/2025
Primary Sponsor
Josh West
Click for details
AI Summary
-
Requires insurers offering group insurance plans for Oklahoma state employees to ensure FDA-approved non-opioid pain treatments are not disadvantaged or discouraged on preferred drug lists relative to opioid or narcotic drugs
-
Defines "non-opioid treatment" as drugs or biological products that produce pain relief without acting on opioid receptors and have no therapeutically equivalent alternatives per FDA publications
-
Permits insurers to prefer certain opioids over other opioids, or certain non-opioids over other non-opioids, but prohibits systematically favoring opioids over non-opioid alternatives
-
Applies to contracts between insurers and pharmacy benefits managers for state employee group insurance plans
-
Effective date: November 1, 2025
Legislative Description
Non-opioid treatment; terms; preferred drug lists; discretion; drug treatment; United States Food and Drug Administration; coverage; non-opioid drugs; reimbursement; effective date.
Last Action
Second Reading referred to Health and Human Services Committee then to Appropriations Committee
4/1/2025